Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., May 01, 2024 -- Denali Therapeutics Inc. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ...
Source: marketscreener.com